Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...

President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...

Marty Makary, likely FDA commissioner under President Trump, appeared before Congress this week as the agency he’s set to lead continues to be rocked by sweeping changes and about-faces.

A federal pharmaceutical testing facility in St. Louis will remain open, despite appearing on DOGE’s list of scheduled office ...

The Senate hearing for FDA Commissioner nominee Marty Makary comes after President Trump's NIH pick, Jay Bhattacharya, was ...

director of the administration's Center for Drug Evaluation and Research (CDER). "Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this ...

DURHAM, N.C. - Biotechnology company Humacyte, Inc. (NASDAQ:HUMA), currently trading at $3.04 and down over 21% in the past week, has announced the commercial launch of its bioengineered human tissue ...

Health experts have slammed the FDA as 'corrupt' and 'in bed with Big Pharma' after its former drug chief Dr Patrizia Cavazzoni left the agency to serve as chief medical officer of Pfizer.

Patrizia Cavazzoni was formerly director of the FDA’s Center for Drug Evaluation and Research (CDER) from 2020 until January, when she resigned just ahead of President Trump’s return to office.

The user fee program framework includes trigger rates that must be met in order for the FDA to access the funding. Without enough staff at the CDER, which receives user fees, the FDA could find ...